Patent SG-11201408123S-A (SG)
Title: Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
Inventor: VAN T KLOOSTER GERBEN ALBERT ELEUTHERIUS
IPC: A61P1/00
Filed: 2013-06-10
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/189771 Al (51) International Patent Classification: A61K 45/06 (2006.01) A61P1/00 (2006.01) A61K31/541 (2006.01) A61P17/06 (2006.01) A61P19/02 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/061914 10 June 2013 (10.06.2013) English (30) Priority Data: 61/663,520 22 June 2012 (22.06.2012) English US (71) Applicant: GALAPAGOS NV [BE/BE]; Industriepark Mechelen Noord, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). (72) Inventors: VAN 'T KLOOSTER, Gerben Albert Eleutherius; Galapagos NV, Generaal De Wittelaan LI 1/A3, B-2800 Mechelen (BE). BRYS, Reginald Chris- tophe Xavier; Galapagos NV, Generaal De Wittelaan LI 1/A3, B-2800 Mechelen (BE). VAN ROMPAEY, Luc Juliaan Corina; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). NAMOUR, Florence Sylvie; Galapagos SASU, 102 Avenue Gaston Roussel, F- 93230 Romainville (FR). (74) Agent: BAR, Gregory; Galapagos NV, Generaal de Witte­ laan, LI 1 A3, B-2800 Mechelen (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: AMINOTRIAZOLOPYRIDINE FOR USE IN THE TREATMENT OF INFLAMMATION, AND PHARMACEUTICAL COMPOSITIONS THEREOF m VN- i> i> o\ 00 i-H en i-H o CJ o & (57) Abstract: The present invention relates to the novel medical use of the compound according to Formula I, in particular in the treatment of inflam­ matory conditions, autoimmune diseases, proliferative diseases, allergy, trans­ plant rejection, diseases involving impairment of cartilage turnover, congenit­ al cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyr­ osine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory con­ ditions, autoimmune diseases, proliferative diseases, allergy, transplant rejec­ tion, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or inter­ ferons by administering the compound. WO 2013/189771 Al I lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll lllll llll llll lllll lllllll llll llll Declarations under Rule 4.17: Published: — as to applicant's entitlement to apply for and be granted — with international search report (Art. 21(3)) a patent (Rule 4.17(H))